Compare
DataMeds AI, Inc. vs Cosmos Health Inc. vs Stemtech Corp vs Nu Skin Enterprises, Inc.
| Latest fiscal year | DataMeds AI, Inc. MEDS | Cosmos Health Inc. COSM | Stemtech Corp STEK | Nu Skin Enterprises, Inc. NUS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $23.34M | $65.27M | $2.88M | $1.49B |
| Revenue growth (YoY) | +28.7% | +19.9% | -43.1% | -14.3% |
| Gross margin | -27.5% | 12.1% | 80.3% | 69.4% |
| Operating margin | -401.7% | -25.6% | -94.2% | 4.4% |
| Net margin | -433.9% | -29.3% | -140.7% | 10.8% |
| Net income | -$101.27M | -$19.14M | -$4.05M | $160.20M |
| EPS (Diluted) | -$1.43 | -$0.63 | -$0.02 | $3.18 |
| Operating cash flow | -$10.86M | -$8.45M | -$483.6K | $80.29M |
| Free cash flow | n/a | -$8.50M | -$483.6K | $46.01M |
| Cash & equivalents | $42.6K | $715.7K | n/a | $238.63M |
| Total assets | $30.46M | $65.48M | $3.15M | $1.41B |
| Total liabilities | $42.91M | $47.05M | $10.59M | $600.07M |
| Shareholders' equity | -$12.45M | $18.42M | -$6.96M | $805.24M |
| Return on year-end equity | n/a | -103.9% | n/a | 19.9% |
| Shares outstanding | 101.31M | 41.07M | 425.98M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | DataMeds AI, Inc. | Cosmos Health Inc. | Stemtech Corp | Nu Skin Enterprises, Inc. |
|---|---|---|---|---|
| Latest | $23.34M Ended 2025-12-31 | $65.27M Ended 2025-12-31 | $2.88M Ended 2025-12-31 | $1.49B Ended 2025-12-31 |
| 1 year earlier | $18.13M Ended 2024-12-31 | $54.43M Ended 2024-12-31 | $5.05M Ended 2024-12-31 | $1.73B Ended 2024-12-31 |
| 2 years earlier | n/a | $53.38M Ended 2023-12-31 | $4.92M Ended 2023-12-31 | $1.97B Ended 2023-12-31 |
| 3 years earlier | n/a | $50.35M Ended 2022-12-31 | $4.56M Ended 2022-12-31 | $2.23B Ended 2022-12-31 |
| 4 years earlier | n/a | $56.24M Ended 2021-12-31 | $4.32M Ended 2021-12-31 | $2.70B Ended 2021-12-31 |